RESTful Lookup — Test-Drive (2007 – 2026)

{
  "NDC": [
    {
      "NDCCode": "51862-896-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-896-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0896-03",
      "ProductNDC": "51862-896",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Tilia Fe",
      "NonProprietaryName": "Ndac And Ee Tablets And Ferrous Fumarate Tablets",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201015",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202962",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Deprecated",
      "LastUpdate": "2025-09-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20251231",
      "StartMarketingDatePackage": "20201015",
      "SamplePackage": "N",
      "IndicationAndUsage": "Tilia Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tilia Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the. percentage who experience an accidental pregnancy during the first year if they do not stop use. for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it. perfectly (both consistently and correctly), the percentage who experience an accidental. pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method. for 1 year. 4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations. where contraception is not used and from women who cease using contraception in order to. become pregnant. Among such populations, about 89% become pregnant within one year. This. estimate was lowered slightly (to 85%) to represent the percent who would become pregnant. within one year among women now relying on reversible methods of contraception if they. abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal. body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second. dose 12 hours after the first dose. The Food and Drug Administration has declared the following. brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1. dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 lightorange. pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil® or Tri-Levlen® (1 dose is 4 yellow. pills). 10 However, to maintain effective protection against pregnancy, another method of contraception. must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is. reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28-day) cycle studies. A total of 296 patients received norethindrone acetate and ethinyl estradiol tablets and 295 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator's global evaluation. Patients with severe androgen excess were not studied. Table 3. Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline* Intent To Treat Population. *Numbers rounded to nearest integer. † Limits for 95% Confidence Interval; not adjusted for baseline differences. Norethindrone acetate and ethinyl estradiol tablet users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment.",
      "Description": "Tilia Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. Tilia Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each pale yellow tablet contains 1 mg norethindrone acetate [(17 alpha)-17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each light brown tablet contains 1mg norethindrone acetate and 35mcg ethinyl estradiol. Each pale yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.Each pale yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide ,Talc, Macrogol/Polyethylene Glycol, Lecithin (Soya),D&C Yellow #10 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Yellow #6 Aluminum Lake. Each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each light yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide , Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), D&C Yellow #10 Aluminum Lake, Iron Oxide Yellow, FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake. Each light brown tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each light brown tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide,Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), Iron Oxide Yellow, Iron Oxide Red, Iron Oxide Black. The structural formulas are as follows. Each brown tablet contains:  Ferrous Fumarate, Micro-crystalline Cellulose, Hydroxypropyl Cellulose, Crospovidone, Magnesium Stearate, Polyvinyl Alcohol, Iron Oxide Yellow, Talc, Polyethylene Glycol 3350, Iron Oxide Red, Lecithin (Soya), Iron Oxide Black. Each Tilia Fe tablet dispenser contains five pale yellow tablets, seven light yellow tablets, nine light brown tablets, and seven brown tablets. These tablets are to be taken in the following order: one pale yellow tablet each day for five days, then one light yellow tablet each day for seven days, followed by one light brown tablet each day for nine days, and then one brown tablet each day for seven days."
    },
    {
      "NDCCode": "51862-896-01",
      "PackageDescription": "1 BLISTER PACK in 1 PACKET (51862-896-01)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0896-01",
      "ProductNDC": "51862-896",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Tilia Fe",
      "NonProprietaryName": "Ndac And Ee Tablets And Ferrous Fumarate Tablets",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201015",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202962",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-09-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201015",
      "SamplePackage": "N",
      "IndicationAndUsage": "Tilia Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tilia Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the. percentage who experience an accidental pregnancy during the first year if they do not stop use. for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it. perfectly (both consistently and correctly), the percentage who experience an accidental. pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method. for 1 year. 4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations. where contraception is not used and from women who cease using contraception in order to. become pregnant. Among such populations, about 89% become pregnant within one year. This. estimate was lowered slightly (to 85%) to represent the percent who would become pregnant. within one year among women now relying on reversible methods of contraception if they. abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal. body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second. dose 12 hours after the first dose. The Food and Drug Administration has declared the following. brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1. dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 lightorange. pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil® or Tri-Levlen® (1 dose is 4 yellow. pills). 10 However, to maintain effective protection against pregnancy, another method of contraception. must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is. reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28-day) cycle studies. A total of 296 patients received norethindrone acetate and ethinyl estradiol tablets and 295 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator's global evaluation. Patients with severe androgen excess were not studied. Table 3. Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline* Intent To Treat Population. *Numbers rounded to nearest integer. † Limits for 95% Confidence Interval; not adjusted for baseline differences. Norethindrone acetate and ethinyl estradiol tablet users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment.",
      "Description": "Tilia Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. Tilia Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each pale yellow tablet contains 1 mg norethindrone acetate [(17 alpha)-17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each light brown tablet contains 1mg norethindrone acetate and 35mcg ethinyl estradiol. Each pale yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.Each pale yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide ,Talc, Macrogol/Polyethylene Glycol, Lecithin (Soya),D&C Yellow #10 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Yellow #6 Aluminum Lake. Each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each light yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide , Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), D&C Yellow #10 Aluminum Lake, Iron Oxide Yellow, FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake. Each light brown tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each light brown tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide,Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), Iron Oxide Yellow, Iron Oxide Red, Iron Oxide Black. The structural formulas are as follows. Each brown tablet contains:  Ferrous Fumarate, Micro-crystalline Cellulose, Hydroxypropyl Cellulose, Crospovidone, Magnesium Stearate, Polyvinyl Alcohol, Iron Oxide Yellow, Talc, Polyethylene Glycol 3350, Iron Oxide Red, Lecithin (Soya), Iron Oxide Black. Each Tilia Fe tablet dispenser contains five pale yellow tablets, seven light yellow tablets, nine light brown tablets, and seven brown tablets. These tablets are to be taken in the following order: one pale yellow tablet each day for five days, then one light yellow tablet each day for seven days, followed by one light brown tablet each day for nine days, and then one brown tablet each day for seven days."
    },
    {
      "NDCCode": "51862-896-02",
      "PackageDescription": "1 BLISTER PACK in 1 CARTON (51862-896-02)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0896-02",
      "ProductNDC": "51862-896",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Tilia Fe",
      "NonProprietaryName": "Ndac And Ee Tablets And Ferrous Fumarate Tablets",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201015",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202962",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-09-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201015",
      "SamplePackage": "N",
      "IndicationAndUsage": "Tilia Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tilia Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the. percentage who experience an accidental pregnancy during the first year if they do not stop use. for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it. perfectly (both consistently and correctly), the percentage who experience an accidental. pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method. for 1 year. 4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations. where contraception is not used and from women who cease using contraception in order to. become pregnant. Among such populations, about 89% become pregnant within one year. This. estimate was lowered slightly (to 85%) to represent the percent who would become pregnant. within one year among women now relying on reversible methods of contraception if they. abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal. body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second. dose 12 hours after the first dose. The Food and Drug Administration has declared the following. brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1. dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 lightorange. pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil® or Tri-Levlen® (1 dose is 4 yellow. pills). 10 However, to maintain effective protection against pregnancy, another method of contraception. must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is. reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28-day) cycle studies. A total of 296 patients received norethindrone acetate and ethinyl estradiol tablets and 295 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator's global evaluation. Patients with severe androgen excess were not studied. Table 3. Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline* Intent To Treat Population. *Numbers rounded to nearest integer. † Limits for 95% Confidence Interval; not adjusted for baseline differences. Norethindrone acetate and ethinyl estradiol tablet users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment.",
      "Description": "Tilia Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. Tilia Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each pale yellow tablet contains 1 mg norethindrone acetate [(17 alpha)-17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each light brown tablet contains 1mg norethindrone acetate and 35mcg ethinyl estradiol. Each pale yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.Each pale yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide ,Talc, Macrogol/Polyethylene Glycol, Lecithin (Soya),D&C Yellow #10 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Yellow #6 Aluminum Lake. Each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each light yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide , Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), D&C Yellow #10 Aluminum Lake, Iron Oxide Yellow, FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake. Each light brown tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each light brown tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide,Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), Iron Oxide Yellow, Iron Oxide Red, Iron Oxide Black. The structural formulas are as follows. Each brown tablet contains:  Ferrous Fumarate, Micro-crystalline Cellulose, Hydroxypropyl Cellulose, Crospovidone, Magnesium Stearate, Polyvinyl Alcohol, Iron Oxide Yellow, Talc, Polyethylene Glycol 3350, Iron Oxide Red, Lecithin (Soya), Iron Oxide Black. Each Tilia Fe tablet dispenser contains five pale yellow tablets, seven light yellow tablets, nine light brown tablets, and seven brown tablets. These tablets are to be taken in the following order: one pale yellow tablet each day for five days, then one light yellow tablet each day for seven days, followed by one light brown tablet each day for nine days, and then one brown tablet each day for seven days."
    },
    {
      "NDCCode": "51862-896-06",
      "PackageDescription": "6 BLISTER PACK in 1 CARTON (51862-896-06)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0896-06",
      "ProductNDC": "51862-896",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Tilia Fe",
      "NonProprietaryName": "Ndac And Ee Tablets And Ferrous Fumarate Tablets",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201015",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202962",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-09-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201015",
      "SamplePackage": "N",
      "IndicationAndUsage": "Tilia Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tilia Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2. Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the. percentage who experience an accidental pregnancy during the first year if they do not stop use. for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it. perfectly (both consistently and correctly), the percentage who experience an accidental. pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method. for 1 year. 4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations. where contraception is not used and from women who cease using contraception in order to. become pregnant. Among such populations, about 89% become pregnant within one year. This. estimate was lowered slightly (to 85%) to represent the percent who would become pregnant. within one year among women now relying on reversible methods of contraception if they. abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal. body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second. dose 12 hours after the first dose. The Food and Drug Administration has declared the following. brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1. dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 lightorange. pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil® or Tri-Levlen® (1 dose is 4 yellow. pills). 10 However, to maintain effective protection against pregnancy, another method of contraception. must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is. reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28-day) cycle studies. A total of 296 patients received norethindrone acetate and ethinyl estradiol tablets and 295 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator's global evaluation. Patients with severe androgen excess were not studied. Table 3. Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline* Intent To Treat Population. *Numbers rounded to nearest integer. † Limits for 95% Confidence Interval; not adjusted for baseline differences. Norethindrone acetate and ethinyl estradiol tablet users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment.",
      "Description": "Tilia Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. Tilia Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each pale yellow tablet contains 1 mg norethindrone acetate [(17 alpha)-17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each light brown tablet contains 1mg norethindrone acetate and 35mcg ethinyl estradiol. Each pale yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.Each pale yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide ,Talc, Macrogol/Polyethylene Glycol, Lecithin (Soya),D&C Yellow #10 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Yellow #6 Aluminum Lake. Each light yellow tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each light yellow tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide , Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), D&C Yellow #10 Aluminum Lake, Iron Oxide Yellow, FD&C Yellow #6 Aluminum Lake, FD&C Blue #2 Aluminum Lake. Each light brown tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each light brown tablet contains the following inactive ingredients: Ethyl Cellulose, Hypromellose, Lactose Monohydrate, Pregelatinized Starch, Magnesium Stearate, Polyvinyl Alcohol, Titanium Dioxide,Talc , Macrogol/Polyethylene Glycol, Lecithin (Soya), Iron Oxide Yellow, Iron Oxide Red, Iron Oxide Black. The structural formulas are as follows. Each brown tablet contains:  Ferrous Fumarate, Micro-crystalline Cellulose, Hydroxypropyl Cellulose, Crospovidone, Magnesium Stearate, Polyvinyl Alcohol, Iron Oxide Yellow, Talc, Polyethylene Glycol 3350, Iron Oxide Red, Lecithin (Soya), Iron Oxide Black. Each Tilia Fe tablet dispenser contains five pale yellow tablets, seven light yellow tablets, nine light brown tablets, and seven brown tablets. These tablets are to be taken in the following order: one pale yellow tablet each day for five days, then one light yellow tablet each day for seven days, followed by one light brown tablet each day for nine days, and then one brown tablet each day for seven days."
    },
    {
      "NDCCode": "52904-896-03",
      "PackageDescription": "1 PACKET in 1 BLISTER PACK (52904-896-03)  > 1 POWDER, FOR SOLUTION in 1 PACKET",
      "NDC11Code": "52904-0896-03",
      "ProductNDC": "52904-896",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Theraflu Daytime Severe Cold And Cough",
      "NonProprietaryName": "Acetaminophen, Dextromethorphan, Phenylephrine",
      "DosageFormName": "POWDER, FOR SOLUTION",
      "RouteName": "ORAL",
      "StartMarketingDate": "20180430",
      "MarketingCategoryName": "OTC MONOGRAPH FINAL",
      "ApplicationNumber": "part341",
      "LabelerName": "Select Corporation",
      "SubstanceName": "ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE",
      "StrengthNumber": "650; 20; 10",
      "StrengthUnit": "mg/1; mg/1; mg/1",
      "Pharm_Classes": "Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",
      "Status": "Deprecated",
      "LastUpdate": "2024-01-02",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20231231",
      "StartMarketingDatePackage": "20180430",
      "SamplePackage": "N",
      "IndicationAndUsage": "temporarily relieves these symptoms due to a cold:minor aches and painsminor sore throat painheadachenasal and sinus congestioncough due to minor throat and bronchial irritation. temporarily reduces fever."
    },
    {
      "NDCCode": "55700-896-03",
      "PackageDescription": "1 BLISTER PACK in 1 CARTON (55700-896-03)  > 3 TABLET, FILM COATED in 1 BLISTER PACK",
      "NDC11Code": "55700-0896-03",
      "ProductNDC": "55700-896",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Azithromycin Dihydrate",
      "NonProprietaryName": "Azithromycin Dihydrate",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20210120",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA208249",
      "LabelerName": "Quality Care Products, LLC",
      "SubstanceName": "AZITHROMYCIN DIHYDRATE",
      "StrengthNumber": "500",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Macrolide Antimicrobial [EPC],Macrolides [CS]",
      "Status": "Deprecated",
      "LastUpdate": "2021-11-16",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20221231",
      "StartMarketingDatePackage": "20210120",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "63545-896-03",
      "PackageDescription": "3000 PELLET in 1 BOTTLE, GLASS (63545-896-03) ",
      "NDC11Code": "63545-0896-03",
      "ProductNDC": "63545-896",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Aluminium Phosphoricum",
      "NonProprietaryName": "Aluminium Phosphoricum",
      "DosageFormName": "PELLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20200429",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "Hahnemann Laboratories, Inc.",
      "SubstanceName": "ALUMINUM PHOSPHATE",
      "StrengthNumber": "10",
      "StrengthUnit": "[hp_M]/1",
      "Status": "Deprecated",
      "LastUpdate": "2022-01-04",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20211231",
      "StartMarketingDatePackage": "20200429",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "65162-896-03",
      "PackageDescription": "30 TABLET in 1 BOTTLE (65162-896-03) ",
      "NDC11Code": "65162-0896-03",
      "ProductNDC": "65162-896",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Aripiprazole",
      "NonProprietaryName": "Aripiprazole",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20160620",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA204838",
      "LabelerName": "Amneal Pharmaceuticals LLC",
      "SubstanceName": "ARIPIPRAZOLE",
      "StrengthNumber": "2",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Atypical Antipsychotic [EPC]",
      "Status": "Active",
      "LastUpdate": "2026-04-06",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20271231",
      "StartMarketingDatePackage": "20160620",
      "SamplePackage": "N",
      "IndicationAndUsage": "Aripiprazole Tablets are indicated for the treatment of: : 1 Schizophrenia , 2 Irritability Associated with Autistic Disorder , 3 Treatment of Tourette’s Disorder.",
      "Description": "Aripiprazole, USP is an atypical antipsychotic drug that is available as aripiprazole tablets, USP. Aripiprazole, USP is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The molecular formula is C23H27Cl2N3O2 and its molecular weight is 448.38. The chemical structure is. Aripiprazole tablets, USP are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Inactive ingredients include croscarmellose sodium, magnesium stearate, microcrystalline cellulose and tartaric acid. The 2 mg and 5 mg tablets contain FD&C Blue No. 2 indigo carmine aluminum lake (30% to 36%). The 2 mg and 15 mg tablets contain ferric oxide yellow. The 10 mg and 30 mg tablets contain FD&C Red No. 40 allura red AC aluminum lake (15% to 17%)."
    },
    {
      "NDCCode": "68428-896-03",
      "PackageDescription": "75 PELLET in 1 VIAL, GLASS (68428-896-03)",
      "NDC11Code": "68428-0896-03",
      "ProductNDC": "68428-896",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Beryllium Metallicum",
      "NonProprietaryName": "Beryllium",
      "DosageFormName": "PELLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20120611",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "Washington Homeopathic Products",
      "SubstanceName": "BERYLLIUM",
      "StrengthNumber": "30",
      "StrengthUnit": "[hp_C]/1",
      "Status": "Deprecated",
      "LastUpdate": "2025-01-01",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20241231",
      "IndicationAndUsage": "Indications. BERYLLIUM   Dry cough."
    },
    {
      "NDCCode": "84682-896-03",
      "PackageDescription": "30 g in 1 BOX (84682-896-03) ",
      "NDC11Code": "84682-0896-03",
      "ProductNDC": "84682-896",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Trstay Carrot Cream",
      "NonProprietaryName": "Trstay Carrot Cream",
      "DosageFormName": "CREAM",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20241101",
      "MarketingCategoryName": "OTC MONOGRAPH DRUG",
      "ApplicationNumber": "M016",
      "LabelerName": "Yiwu Xinqian E Commerce Co Ltd",
      "SubstanceName": "NIACINAMIDE",
      "StrengthNumber": "5",
      "StrengthUnit": "g/100g",
      "Status": "Deprecated",
      "LastUpdate": "2024-12-27",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20251231",
      "StartMarketingDatePackage": "20241101",
      "SamplePackage": "N",
      "IndicationAndUsage": "Apply twice daly(moring and night as a man and once as a woman.Afer apicaion, proeed with an acive masage for 3-5 minutes unthe product is fuy absorbed."
    },
    {
      "NDCCode": "51862-036-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-036-03)  > 1 KIT in 1 BLISTER PACK (51862-036-01) ",
      "NDC11Code": "51862-0036-03",
      "ProductNDC": "51862-036",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Zarah",
      "NonProprietaryName": "Drospirenone And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20160803",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA090081",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Deprecated",
      "LastUpdate": "2022-01-04",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20211231",
      "StartMarketingDatePackage": "20160803",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "51862-148-03",
      "PackageDescription": "3 POUCH in 1 CARTON (51862-148-03)  / 21 d in 1 POUCH (51862-148-01) ",
      "NDC11Code": "51862-0148-03",
      "ProductNDC": "51862-148",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Haloette",
      "NonProprietaryName": "Etonogestrel And Ethinyl Estradiol",
      "DosageFormName": "INSERT, EXTENDED RELEASE",
      "RouteName": "VAGINAL",
      "StartMarketingDate": "20221201",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA211328",
      "LabelerName": "Mayne Pharma Inc.",
      "SubstanceName": "ETHINYL ESTRADIOL; ETONOGESTREL",
      "StrengthNumber": ".015; .12",
      "StrengthUnit": "mg/d; mg/d",
      "Pharm_Classes": "Estrogen Receptor Agonists [MoA], Estrogen [EPC], Progesterone Congeners [CS], Progestin [EPC]",
      "Status": "Deprecated",
      "LastUpdate": "2025-07-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20251231",
      "StartMarketingDatePackage": "20221201",
      "SamplePackage": "N",
      "IndicationAndUsage": "FOR VAGINAL USE ONLY. Haloette® is indicated for use by females of reproductive age to prevent pregnancy.",
      "Description": "Haloette (etonogestrel and ethinyl estradiol vaginal ring) is a non-biodegradable, flexible, transparent, colorless to almost colorless, combination contraceptive vaginal ring containing two active components, a progestin, etonogestrel (13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-3-one) and an estrogen, ethinyl estradiol (19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol). When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Haloette is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. Haloette is not made with natural rubber latex. Haloette has an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. The molecular weights for etonogestrel and ethinyl estradiol are 324.46 and 296.40, respectively. The structural formulas are as follows."
    },
    {
      "NDCCode": "51862-238-03",
      "PackageDescription": "3 POUCH in 1 CARTON (51862-238-03)  > 1 BLISTER PACK in 1 POUCH (51862-238-01)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0238-03",
      "ProductNDC": "51862-238",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Caziant",
      "ProprietaryNameSuffix": "Triphasic Regimen",
      "NonProprietaryName": "Desogestrel And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20160803",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076455",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Deprecated",
      "LastUpdate": "2022-08-23",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20221231",
      "StartMarketingDatePackage": "20160803",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "51862-284-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-284-03)  > 1 KIT in 1 BLISTER PACK (51862-284-01) ",
      "NDC11Code": "51862-0284-03",
      "ProductNDC": "51862-284",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Tilia Fe",
      "NonProprietaryName": "Norethindrone Acetate And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "RouteName": "ORAL",
      "StartMarketingDate": "20160805",
      "EndMarketingDate": "20211231",
      "MarketingCategoryName": "NDA",
      "ApplicationNumber": "NDA020130",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Deprecated",
      "LastUpdate": "2022-01-04",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "StartMarketingDatePackage": "20160805",
      "EndMarketingDatePackage": "20211231",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "51862-318-03",
      "PackageDescription": "3 POUCH in 1 CARTON (51862-318-03)  > 1 BLISTER PACK in 1 POUCH (51862-318-01)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0318-03",
      "ProductNDC": "51862-318",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Necon",
      "ProprietaryNameSuffix": "(28 Day Regimen)",
      "NonProprietaryName": "Norethindrone And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20160718",
      "EndMarketingDate": "20220430",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA072695",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Deprecated",
      "LastUpdate": "2022-05-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "StartMarketingDatePackage": "20160718",
      "EndMarketingDatePackage": "20220430",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "51862-514-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-514-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0514-03",
      "ProductNDC": "51862-514",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Desogestrel And Ethinyl Estradiol",
      "NonProprietaryName": "Desogestrel And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201004",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA091234",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2022-12-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201004",
      "SamplePackage": "N",
      "IndicationAndUsage": "Desogestrel and ethinyl estradiol tablets, USP are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates. In a clinical trial with desogestrel and ethinyl estradiol tablets 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. This represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. This rate includes patients who did not take the drug correctly. Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.9. Lactational Amenorrhea Method: LAM is highly effective, temporary method of contraception.10. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. 4 The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The FDA has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 yellow pills). 10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency of duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Desogestrel and ethinyl estradiol tablets have not been studied for and is not indicated for use in emergency contraception.",
      "Description": "Desogestrel and ethinyl estradiol tablets, USP provide an oral contraceptive regimen of 21 orange tablets each containing 0.15 mg desogestrel (13-ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol), and 0.03 mg ethinyl estradiol (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3,17, diol). Each \"active\" orange tablet with \"S3\" debossed on one side contains the following inactive ingredients: lactose monohydrate, pregelatinized corn starch, povidone, stearic acid, vitamin E, HPMC/hypromellose, titanium dioxide, macrogol/polyethylene glycol, D&C Yellow #10 Aluminum Lake, FD&C Yellow #6 Aluminium Lake, Iron Oxide Yellow, FD&C Red #40 Aluminum Lake, FD&C Blue #2 Aluminum Lake. Each \"inactive\" reminder white, biconvex, round tablets with \"P\" debossed on one side and \"N\" on the other side contains the following inactive ingredients: titanium dioxide, polydextrose, hypromellose, triacetin, polyethylene glycol, lactose, magnesium stearate, and pregelatinized corn starch. The 21 orange tablets meet USP Dissolution Test 2."
    },
    {
      "NDCCode": "51862-645-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-645-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0645-03",
      "ProductNDC": "51862-645",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Nymyo",
      "NonProprietaryName": "Norgestimate And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201011",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA090523",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2022-12-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201011",
      "SamplePackage": "N",
      "IndicationAndUsage": "Nymyo is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. (1.1).",
      "Description": "Nymyo is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). : 1 Each active blue tablet contains 0.250 mg of norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include: FD&C Blue No. 2 Aluminium Lake, FD&C Blue No. 1 Aluminum lake, FD&C Red No. 40 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake, titanium dioxide, polyvinyl alcohol, talc, macrogol/PEG 3350 NF, lecithin, lactose monohydrate, magnesium stearate and pregelatinized corn starch., 2 Each white placebo tablet containing only inert ingredients, as follows: titanium dioxide, polydextrose, hypromellose, triacetin, macrogol/polyethylene glycol, lactose monohydrate, magnesium stearate and pregelatinized corn starch."
    },
    {
      "NDCCode": "51862-646-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-646-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0646-03",
      "ProductNDC": "51862-646",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Tri-nymyo",
      "NonProprietaryName": "Norgestimate And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201024",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA090524",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2022-12-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201024",
      "SamplePackage": "N",
      "IndicationAndUsage": "Tri-Nymyo is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. (1.1). Tri-Nymyo is also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Nymyo should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. (1.2).",
      "Description": "Tri-Nymyo is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17 )-(+)-) and ethinyl estradiol is designated as (19-nor-17 -pregna,1,3,5(10)-trien-20-yne-3,17-diol). : 1 Each active green tablet contains 0.18 mg of norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include: FD&C Blue No.2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake, titanium dioxide, iron oxide black,iron oxide yellow, macrogol/ polyethylene glycol 3350 NF, lecithin, talc, polyvinyl alcohol,lactose monohydrate, magnesium stearate and pregelatinized corn starch., 2 Each active light blue tablet contains 0.215 mg of norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include: FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake, titanium dioxide, iron oxide black, polyvinyl alcohol, talc, macrogol/polyethylene glycol 3350 NF, lecithin, lactose monohydrate, magnesium stearate and pregelatinized corn starch., 3 Each active blue tablet contains 0.25 mg of norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include: FD&C Blue No. 2 Aluminium Lake, FD&C Blue No. 1 Aluminum lake, FD&C Red No. 40 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake,titanium dioxide, polyvinyl alcohol, talc, macrogol/PEG 3350 NF, lecithin, lactose monohydrate, magnesium stearate and pregelatinized corn starch., 4 Each white placebo tablet containing only inert ingredients, as follows: titanium dioxide, polydextrose, hypromellose, triacetin, macrogol/polyethylene glycol, lactose monohydrate, magnesium stearate and pregelatinized corn starch."
    },
    {
      "NDCCode": "51862-648-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-648-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0648-03",
      "ProductNDC": "51862-648",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Microgestin 24 Fe",
      "NonProprietaryName": "Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201012",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202994",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2020-11-13",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201012",
      "SamplePackage": "N",
      "IndicationAndUsage": "Microgestin 24 Fe is a progestin/estrogen COC indicated for use by women to prevent pregnancy. (1). The efficacy of Microgestin 24 Fe in women with a body mass index (BMI) of >35 kg/m2 has not been evaluated. (1, 8.8).",
      "Description": "Microgestin 24 Fe is a combination oral contraceptive for oral administration consisting of active tablets containing norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, and placebo tablets containing ferrous fumarate, which serve no therapeutic purpose. : 1 Each active pale yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Inactive ingredients include polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350 NF, lecithin (soya), D&C Yellow No.10 Aluminum Lake, FD&C Blue No.2 Aluminum Lake, FD&C Yellow No.6 Aluminum Lake, lactose, magnesium stearate and pregelatinized corn starch., 2 Each placebo brown tablet contains 75 mg ferrous fumarate, polyvinyl alcohol, iron oxide yellow, talc, macrogol/polyethylene glycol 3350 NF, iron oxide red, lecithin (soya), iron oxide black, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate and crospovidone.. The ferrous fumarate tablets do not serve any therapeutic purpose. Ferrous fumarate tablets are not USP for dissolution."
    },
    {
      "NDCCode": "51862-866-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-866-03)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0866-03",
      "ProductNDC": "51862-866",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Microgestin Fe 1/20",
      "NonProprietaryName": "Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201012",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA091454",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-08-12",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201012",
      "SamplePackage": "N",
      "IndicationAndUsage": "Microgestin Fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.",
      "Description": "Microgestin Fe 1/20 is progestogen-estrogen combination. Microgestin Fe 1/20: Each provides a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each pale yellow tablet contains norethindrone acetate (17 alpha-ethinyl-19-nortestosterone acetate), 1 mg; ethinyl estradiol (17 alpha-ethinyl-1,3,5(10)-estratriene-3, 17 beta-diol), 20 mcg. Also contains polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350 NF,lecithin (soya), D&C Yellow No.10 Aluminum Lake, FD&C Blue No.2 Aluminum Lake, FD&CYellow No.6 Aluminum Lake, lactose, magnesium stearate and pregelatinized corn starch. The structural formulas are as follows. Each brown placebo tablet contains ferrous fumarate, polyvinyl alcohol,Talc, macrogol/polyethyleneglycol 3350 NF, lecithin (soya),iron oxide black ,iron oxide yellow, microcrystalline cellulose,hydroxypropyl cellulose, magnesium stearate and crospovidone."
    },
    {
      "NDCCode": "51862-868-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-868-03)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0868-03",
      "ProductNDC": "51862-868",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Microgestin 1/20",
      "NonProprietaryName": "Norethindrone Acetate/ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201012",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202995",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-11-14",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201012",
      "SamplePackage": "N",
      "IndicationAndUsage": "Microgestin 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.",
      "Description": "Microgestin 1/20 is a progestogen-estrogen combination. Microgestin 1/20 provides a continuous dosage regimen consisting of 21 pale yellow oral contraceptive tablets. Each pale yellow tablet contains norethindrone acetate (17 alpha-ethinyl-19-nortestosterone acetate), 1 mg; ethinyl estradiol (17 alpha-ethinyl-1,3,5(10)-estratriene-3, 17 beta-diol), 20mcg. Also contains polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350 NF, lecithin (soya), D&C Yellow No.10 Aluminum Lake, FD&C Blue No.2 Aluminum Lake, FD&C Yellow No.6 Aluminum Lake, lactose, magnesium stearate and pregelatinized corn starch. The structural formulas are as follows."
    },
    {
      "NDCCode": "51862-870-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-870-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0870-03",
      "ProductNDC": "51862-870",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Microgestin Fe 1.5/30",
      "NonProprietaryName": "Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201012",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA091453",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2020-10-29",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201012",
      "SamplePackage": "N",
      "IndicationAndUsage": "Microgestin Fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.",
      "Description": "Microgestin Fe 1.5/30 is progestogen-estrogen combination. Microgestin Fe 1.5/30: Each provides a continuous dosage regimen consisting of 21 yellow oral contraceptive tablets and seven brown ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each yellow tablet contains norethindrone acetate (17 alpha-ethinyl-19-nortestosterone acetate), 1.5 mg; ethinyl estradiol (17 alpha-ethinyl-1,3,5(10)-estratriene-3, 17 beta-diol), 30 mcg. Also contains polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350 NF,lecithin (soya), iron oxide yellow, FD&C Blue No.2 Aluminum Lake, D&C Yellow No.10 Aluminum Lake,FD&C Yellow No.6 Aluminum Lake, lactose, magnesium stearate and pregelatinized corn starch. The structural formulas are as follows. Each brown placebo tablet contains ferrous fumarate, polyvinyl alcohol,Talc, macrogol/polyethyleneglycol 3350 NF, lecithin (soya),iron oxide black ,iron oxide yellow, microcrystalline cellulose,hydroxypropyl cellulose, magnesium stearate and crospovidone."
    },
    {
      "NDCCode": "51862-872-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-872-03)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0872-03",
      "ProductNDC": "51862-872",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Microgestin 1.5/30",
      "NonProprietaryName": "Norethindrone Acetate/ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201011",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202996",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-07-12",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201011",
      "SamplePackage": "N",
      "IndicationAndUsage": "Microgestin 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.",
      "Description": "Microgestin 1.5/30 is a progestogen-estrogen combination. Microgestin 1.5/30 provides a continuous dosage regimen consisting of 21 yellow oral contraceptive tablets. Each yellow tablet contains norethindrone acetate (17 alpha-ethinyl-19-nortestosterone acetate), 1.5 mg; ethinyl estradiol (17 alpha-ethinyl-1,3,5(10)-estratriene-3, 17 beta-diol), 30mcg. Also contains polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350 NF, lecithin (soya), iron oxide yellow, FD&C Blue No.2 Aluminum Lake, D&C Yellow No.10 Aluminum Lake, FD&C Yellow No.6 Aluminum Lake, lactose, magnesium stearate and pregelatinized corn starch. The structural formulas are as follows."
    },
    {
      "NDCCode": "51862-884-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-884-03)  / 28 TABLET in 1 BLISTER PACK (51862-884-01) ",
      "NDC11Code": "51862-0884-03",
      "ProductNDC": "51862-884",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Camila",
      "NonProprietaryName": "Norethindrone",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20180615",
      "EndMarketingDate": "20260831",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076177",
      "LabelerName": "Mayne Pharma Inc.",
      "SubstanceName": "NORETHINDRONE",
      "StrengthNumber": ".35",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Progesterone Congeners [CS], Progestin [EPC]",
      "Status": "Deprecated",
      "LastUpdate": "2026-09-01",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "StartMarketingDatePackage": "20180615",
      "EndMarketingDatePackage": "20260831",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "51862-886-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-886-03)  / 28 TABLET in 1 BLISTER PACK (51862-886-01) ",
      "NDC11Code": "51862-0886-03",
      "ProductNDC": "51862-886",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Errin",
      "NonProprietaryName": "Norethindrone",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20180418",
      "EndMarketingDate": "20260831",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076225",
      "LabelerName": "Mayne Pharma Inc.",
      "SubstanceName": "NORETHINDRONE",
      "StrengthNumber": ".35",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Progesterone Congeners [CS], Progestin [EPC]",
      "Status": "Deprecated",
      "LastUpdate": "2026-09-01",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "StartMarketingDatePackage": "20180418",
      "EndMarketingDatePackage": "20260831",
      "SamplePackage": "N"
    },
    {
      "NDCCode": "51862-890-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-890-03)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0890-03",
      "ProductNDC": "51862-890",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Azurette",
      "NonProprietaryName": "Desogestrel/ethinyl Estradiol And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201003",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA091247",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-09-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201003",
      "SamplePackage": "N",
      "IndicationAndUsage": "Azurette (Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates. Adapted from Hatcher et al., 1998, Ref#1. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. 4 The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides."
    },
    {
      "NDCCode": "51862-892-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-892-03)  > 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0892-03",
      "ProductNDC": "51862-892",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Necon",
      "NonProprietaryName": "Norethindrone And Ethinyl Estradiol",
      "DosageFormName": "KIT",
      "RouteName": "ORAL",
      "StartMarketingDate": "20201012",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA091204",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Deprecated",
      "LastUpdate": "2025-09-10",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20251231",
      "StartMarketingDatePackage": "20201012",
      "SamplePackage": "N",
      "IndicationAndUsage": "Necon Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT® System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Necon has not been studied for and is not indicated for use in emergency contraception."
    },
    {
      "NDCCode": "51862-894-03",
      "PackageDescription": "3 BLISTER PACK in 1 CARTON (51862-894-03)  / 1 KIT in 1 BLISTER PACK",
      "NDC11Code": "51862-0894-03",
      "ProductNDC": "51862-894",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Zovia 1/35",
      "NonProprietaryName": "Ethynodiol Diacetate And Ethinyl Estradiol Tablets",
      "DosageFormName": "KIT",
      "StartMarketingDate": "20201016",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA209548",
      "LabelerName": "Mayne Pharma Inc.",
      "Status": "Active",
      "LastUpdate": "2025-11-13",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20201016",
      "SamplePackage": "N",
      "IndicationAndUsage": "Zovia 1/35 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. (A) Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (B) Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (C) Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. (D) The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. (E) Foams, creams, gels, vaginal suppositories, and vaginal film. (F) Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. (G) With spermicidal cream or jelly. (H) Without spermicides. (I) The treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), Alesse (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 yellow pills). (J) However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age.",
      "Description": "Zovia 1/35: Each pale pink tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol, and the inactive ingredients include lactose monohydrate, pregelatinized starch, vitamin e, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, povidone, polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol/macrogol, lecithin (soya), FD&C Red #40 aluminum lake, FD&C Blue #1 aluminum lake, and FD&C yellow #6 aluminum lake.  Each white tablet in the Zovia 1/35 package is a placebo containing no active ingredients and the inactive ingredients include lactose monohydrate, magnesium stearate, pregelatinized starch, titanium dioxide, polydextrose, hypromellose, triacetin, and polyethylene glycol. The chemical name for ethynodiol diacetate is 19-Nor-17α-pregn-4-en-20-yne-3β,17-diol diacetate, and for ethinyl estradiol it is 19-Nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The structural formulas are as follows. Therapeutic class: Oral contraceptive."
    },
    {
      "NDCCode": "19515-896-11",
      "PackageDescription": "1 VIAL, MULTI-DOSE in 1 CARTON (19515-896-11)  > 5 mL in 1 VIAL, MULTI-DOSE (19515-896-01)",
      "NDC11Code": "19515-0896-11",
      "ProductNDC": "19515-896",
      "ProductTypeName": "VACCINE",
      "ProprietaryName": "Flulaval Quadrivalent",
      "ProprietaryNameSuffix": "2017/2018",
      "NonProprietaryName": "Influenza Virus Vaccine",
      "DosageFormName": "SUSPENSION",
      "RouteName": "INTRAMUSCULAR",
      "StartMarketingDate": "20170707",
      "MarketingCategoryName": "BLA",
      "ApplicationNumber": "BLA125163",
      "LabelerName": "ID Biomedical Corporation of Quebec",
      "SubstanceName": "INFLUENZA A VIRUS A/SINGAPORE/GP1908/2015 IVR-180 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED); INFLUENZA A VIRUS A/HONG KONG/4801/2014 X-263B (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (UV, FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/BRISBANE/60/2008 ANTIGEN (UV, FORMALDEHYDE INACTIVATED)",
      "StrengthNumber": "15; 15; 15; 15",
      "StrengthUnit": "ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL",
      "Status": "Deprecated",
      "LastUpdate": "2018-07-03",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20181231"
    },
    {
      "NDCCode": "30775-053-02",
      "PackageDescription": "12 TUBE in 1 BOX (30775-053-02)  > 58.896 g in 1 TUBE",
      "NDC11Code": "30775-0053-02",
      "ProductNDC": "30775-053",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Helix",
      "NonProprietaryName": "Cbd Therapy Cream",
      "DosageFormName": "CREAM",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20210901",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part356",
      "LabelerName": "Parker Laboratories, Inc.",
      "SubstanceName": "MENTHOL, UNSPECIFIED FORM",
      "StrengthNumber": "7.4",
      "StrengthUnit": "g/100g",
      "Status": "Deprecated",
      "LastUpdate": "2023-01-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20221231",
      "StartMarketingDatePackage": "20211004",
      "SamplePackage": "N"
    }
  ]
}
                    

{"NDC":[{"NDCCode":"51862-896-03","ProprietaryName":"Tilia Fe","NonProprietaryName":"Ndac And Ee Tablets And Ferrous Fumarate Tablets"},{"NDCCode":"51862-896-01","ProprietaryName":"Tilia Fe","NonProprietaryName":"Ndac And Ee Tablets And Ferrous Fumarate Tablets"},{"NDCCode":"51862-896-02","ProprietaryName":"Tilia Fe","NonProprietaryName":"Ndac And Ee Tablets And Ferrous Fumarate Tablets"},{"NDCCode":"51862-896-06","ProprietaryName":"Tilia Fe","NonProprietaryName":"Ndac And Ee Tablets And Ferrous Fumarate Tablets"},{"NDCCode":"52904-896-03","ProprietaryName":"Theraflu Daytime Severe Cold And Cough","NonProprietaryName":"Acetaminophen, Dextromethorphan, Phenylephrine"},{"NDCCode":"55700-896-03","ProprietaryName":"Azithromycin Dihydrate","NonProprietaryName":"Azithromycin Dihydrate"},{"NDCCode":"63545-896-03","ProprietaryName":"Aluminium Phosphoricum","NonProprietaryName":"Aluminium Phosphoricum"},{"NDCCode":"65162-896-03","ProprietaryName":"Aripiprazole","NonProprietaryName":"Aripiprazole"},{"NDCCode":"68428-896-03","ProprietaryName":"Beryllium Metallicum","NonProprietaryName":"Beryllium"},{"NDCCode":"84682-896-03","ProprietaryName":"Trstay Carrot Cream","NonProprietaryName":"Trstay Carrot Cream"},{"NDCCode":"51862-036-03","ProprietaryName":"Zarah","NonProprietaryName":"Drospirenone And Ethinyl Estradiol"},{"NDCCode":"51862-148-03","ProprietaryName":"Haloette","NonProprietaryName":"Etonogestrel And Ethinyl Estradiol"},{"NDCCode":"51862-238-03","ProprietaryName":"Caziant","NonProprietaryName":"Desogestrel And Ethinyl Estradiol"},{"NDCCode":"51862-284-03","ProprietaryName":"Tilia Fe","NonProprietaryName":"Norethindrone Acetate And Ethinyl Estradiol"},{"NDCCode":"51862-318-03","ProprietaryName":"Necon","NonProprietaryName":"Norethindrone And Ethinyl Estradiol"},{"NDCCode":"51862-514-03","ProprietaryName":"Desogestrel And Ethinyl Estradiol","NonProprietaryName":"Desogestrel And Ethinyl Estradiol"},{"NDCCode":"51862-645-03","ProprietaryName":"Nymyo","NonProprietaryName":"Norgestimate And Ethinyl Estradiol"},{"NDCCode":"51862-646-03","ProprietaryName":"Tri-nymyo","NonProprietaryName":"Norgestimate And Ethinyl Estradiol"},{"NDCCode":"51862-648-03","ProprietaryName":"Microgestin 24 Fe","NonProprietaryName":"Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate"},{"NDCCode":"51862-866-03","ProprietaryName":"Microgestin Fe 1/20","NonProprietaryName":"Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate"},{"NDCCode":"51862-868-03","ProprietaryName":"Microgestin 1/20","NonProprietaryName":"Norethindrone Acetate/ethinyl Estradiol"},{"NDCCode":"51862-870-03","ProprietaryName":"Microgestin Fe 1.5/30","NonProprietaryName":"Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate"},{"NDCCode":"51862-872-03","ProprietaryName":"Microgestin 1.5/30","NonProprietaryName":"Norethindrone Acetate/ethinyl Estradiol"},{"NDCCode":"51862-884-03","ProprietaryName":"Camila","NonProprietaryName":"Norethindrone"},{"NDCCode":"51862-886-03","ProprietaryName":"Errin","NonProprietaryName":"Norethindrone"},{"NDCCode":"51862-890-03","ProprietaryName":"Azurette","NonProprietaryName":"Desogestrel/ethinyl Estradiol And Ethinyl Estradiol"},{"NDCCode":"51862-892-03","ProprietaryName":"Necon","NonProprietaryName":"Norethindrone And Ethinyl Estradiol"},{"NDCCode":"51862-894-03","ProprietaryName":"Zovia 1/35","NonProprietaryName":"Ethynodiol Diacetate And Ethinyl Estradiol Tablets"},{"NDCCode":"19515-896-11","ProprietaryName":"Flulaval Quadrivalent","NonProprietaryName":"Influenza Virus Vaccine"},{"NDCCode":"30775-053-02","ProprietaryName":"Helix","NonProprietaryName":"Cbd Therapy Cream"}]}
                    

<NDCList><NDC><NDCCode>51862-896-03</NDCCode><ProprietaryName>Tilia Fe</ProprietaryName><NonProprietaryName>Ndac And Ee Tablets And Ferrous Fumarate Tablets</NonProprietaryName></NDC><NDC><NDCCode>51862-896-01</NDCCode><ProprietaryName>Tilia Fe</ProprietaryName><NonProprietaryName>Ndac And Ee Tablets And Ferrous Fumarate Tablets</NonProprietaryName></NDC><NDC><NDCCode>51862-896-02</NDCCode><ProprietaryName>Tilia Fe</ProprietaryName><NonProprietaryName>Ndac And Ee Tablets And Ferrous Fumarate Tablets</NonProprietaryName></NDC><NDC><NDCCode>51862-896-06</NDCCode><ProprietaryName>Tilia Fe</ProprietaryName><NonProprietaryName>Ndac And Ee Tablets And Ferrous Fumarate Tablets</NonProprietaryName></NDC><NDC><NDCCode>52904-896-03</NDCCode><ProprietaryName>Theraflu Daytime Severe Cold And Cough</ProprietaryName><NonProprietaryName>Acetaminophen, Dextromethorphan, Phenylephrine</NonProprietaryName></NDC><NDC><NDCCode>55700-896-03</NDCCode><ProprietaryName>Azithromycin Dihydrate</ProprietaryName><NonProprietaryName>Azithromycin Dihydrate</NonProprietaryName></NDC><NDC><NDCCode>63545-896-03</NDCCode><ProprietaryName>Aluminium Phosphoricum</ProprietaryName><NonProprietaryName>Aluminium Phosphoricum</NonProprietaryName></NDC><NDC><NDCCode>65162-896-03</NDCCode><ProprietaryName>Aripiprazole</ProprietaryName><NonProprietaryName>Aripiprazole</NonProprietaryName></NDC><NDC><NDCCode>68428-896-03</NDCCode><ProprietaryName>Beryllium Metallicum</ProprietaryName><NonProprietaryName>Beryllium</NonProprietaryName></NDC><NDC><NDCCode>84682-896-03</NDCCode><ProprietaryName>Trstay Carrot Cream</ProprietaryName><NonProprietaryName>Trstay Carrot Cream</NonProprietaryName></NDC><NDC><NDCCode>51862-036-03</NDCCode><ProprietaryName>Zarah</ProprietaryName><NonProprietaryName>Drospirenone And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-148-03</NDCCode><ProprietaryName>Haloette</ProprietaryName><NonProprietaryName>Etonogestrel And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-238-03</NDCCode><ProprietaryName>Caziant</ProprietaryName><NonProprietaryName>Desogestrel And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-284-03</NDCCode><ProprietaryName>Tilia Fe</ProprietaryName><NonProprietaryName>Norethindrone Acetate And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-318-03</NDCCode><ProprietaryName>Necon</ProprietaryName><NonProprietaryName>Norethindrone And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-514-03</NDCCode><ProprietaryName>Desogestrel And Ethinyl Estradiol</ProprietaryName><NonProprietaryName>Desogestrel And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-645-03</NDCCode><ProprietaryName>Nymyo</ProprietaryName><NonProprietaryName>Norgestimate And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-646-03</NDCCode><ProprietaryName>Tri-nymyo</ProprietaryName><NonProprietaryName>Norgestimate And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-648-03</NDCCode><ProprietaryName>Microgestin 24 Fe</ProprietaryName><NonProprietaryName>Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate</NonProprietaryName></NDC><NDC><NDCCode>51862-866-03</NDCCode><ProprietaryName>Microgestin Fe 1/20</ProprietaryName><NonProprietaryName>Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate</NonProprietaryName></NDC><NDC><NDCCode>51862-868-03</NDCCode><ProprietaryName>Microgestin 1/20</ProprietaryName><NonProprietaryName>Norethindrone Acetate/ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-870-03</NDCCode><ProprietaryName>Microgestin Fe 1.5/30</ProprietaryName><NonProprietaryName>Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate</NonProprietaryName></NDC><NDC><NDCCode>51862-872-03</NDCCode><ProprietaryName>Microgestin 1.5/30</ProprietaryName><NonProprietaryName>Norethindrone Acetate/ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-884-03</NDCCode><ProprietaryName>Camila</ProprietaryName><NonProprietaryName>Norethindrone</NonProprietaryName></NDC><NDC><NDCCode>51862-886-03</NDCCode><ProprietaryName>Errin</ProprietaryName><NonProprietaryName>Norethindrone</NonProprietaryName></NDC><NDC><NDCCode>51862-890-03</NDCCode><ProprietaryName>Azurette</ProprietaryName><NonProprietaryName>Desogestrel/ethinyl Estradiol And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-892-03</NDCCode><ProprietaryName>Necon</ProprietaryName><NonProprietaryName>Norethindrone And Ethinyl Estradiol</NonProprietaryName></NDC><NDC><NDCCode>51862-894-03</NDCCode><ProprietaryName>Zovia 1/35</ProprietaryName><NonProprietaryName>Ethynodiol Diacetate And Ethinyl Estradiol Tablets</NonProprietaryName></NDC><NDC><NDCCode>19515-896-11</NDCCode><ProprietaryName>Flulaval Quadrivalent</ProprietaryName><NonProprietaryName>Influenza Virus Vaccine</NonProprietaryName></NDC><NDC><NDCCode>30775-053-02</NDCCode><ProprietaryName>Helix</ProprietaryName><NonProprietaryName>Cbd Therapy Cream</NonProprietaryName></NDC></NDCList>